Interestingly, most nonpersistent patients (56%) omitted treatment once during follow-up; among them, the number of therapy-discontinuation days was low (4% of the indicated days of therapy) but impacted negatively on the disease prognosis.
The fourth sensitivity analysis assessed the robustness of the medication gap used to signal medication discontinuation (>30 days) by repeating the analyses with the more customary "longer-than-14-day" medication gap.
Current recommendations given to patients regarding natural product use include a statement recommending discontinuation 14 days prior to surgery.
Importantly, to ensure complete washout at the time of scanning among patients under current treatment, compliance with treatment discontinuation 3 days before each PET scan was verified through urine screening.
We requested standardized information on gastrointestinal toxicity outcomes, including hospitalizations, discontinuations, and days with nausea/vomiting, diarrhea, or both.
The median duration between MSC administration and immunosuppressive therapy discontinuation was 324 days (range, 200 550 days).
The median time to discontinuation was 95 days in DLX-treated patients, 90 days in VLX-treated patients, 90 days in ECP-treated patients, and 90 days in GSSRI-treated patients.
For infliximab, the mean time to discontinuation was 931 days (95% CI 844 1018 days), with 32 (27%) of 118 patients discontinuing infliximab.
For etanercept, the mean time to discontinuation was 595 days (95% CI 491 700 days), with 58 (64%) of 90 patients discontinuing etanercept [ 25].
The average time until discontinuation was 156 days for exenatide-treated patients and 111 days for glargine-treated patients (p < 0.0001).
